CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.
Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose ...
A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.
A mismatch between two common tests for kidney function may indicate a higher risk for kidney failure, heart disease, and ...
Proton pump inhibitors (PPIs) do not appear to worsen kidney function compared with the histamine 2 receptor blocker ranitidine based on two measures, a large cohort study from Spain finds. In fact, ...
Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting VIVIAD analyses continue to support ...
Please provide your email address to receive an email when new articles are posted on . The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney ...
Heart failure patients treated with finerenone (Kerendia; Bayer AG) are more likely to have an early decline in kidney function than those treated with placebo, but the decline should not be construed ...
Nine out of 10 people with chronic kidney disease only find out when it progresses to later stages. Here’s what we know about its risk factors—and why there's new reason to hope for more effective ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback